Management of anaemia in renal failure.
The management of renal anaemia has been transformed over the last decade by the advent of recombinant human erythropoietin (EPO) therapy. In relation to the use of erythropoietin, three major topics have emerged which have stimulated the most discussion and controversy. This article explores these three areas: the use of EPO in pre-dialysis patients, iron management in patients receiving EPO therapy, and target haemoglobin.